REVIEW PAPER
Health problems of patients with Huntington’s disease and their impact on daily activity
1
Samodzielna Pracownia Rehabilitacji Neurologicznej, Uniwersytet Medyczny w Lublinie
2
Zakład Balneoterapii, Uniwersytet Medyczny w Lublinie
Corresponding author
Dorota Kozak-Putowska
Samodzielna Pracownia Rehabilitacji Neurologicznej, Uniwersytet Medyczny w Lublinie
Samodzielna Pracownia Rehabilitacji Neurologicznej, Uniwersytet Medyczny w Lublinie
Med Og Nauk Zdr. 2016;22(2):94-97
KEYWORDS
ABSTRACT
Huntington’s disease is an autosomal dominant, inherited, neurodegenerative disorder that manifests with progressive motor, cognitive and psychiatric symptoms.
Huntington’s disease is a physically, psychologically and socially devastating disorder. Depending at what stage of the disease in the patient, preclinical or clinical, health problems are more or less severe. Progressive motor symptoms hinder the independent daily functioning, whereas depression, psychiatric and cognitive dysfunctions are the reason of isolation and avoidance of contact with the environment. At present, there is no effective treatment for the disease, and the drugs applied in therapy have many adverse effects. This leads to progressive failure, depending on caregivers, and consequently to death.
REFERENCES (24)
1.
Nicewicz B, Pełka-Wysiecka J. Neuropsychiatryczne aspekty choroby Huntingtona – opis przypadku. Post Psychiatr Neurol. 2008; 17(1): 89–92.
2.
Bano D, Zanetti F, Mende Y, et al. Neurodegenerative processes in Huntington’s disease. Cell Death Dis. 2011; 2: 1–7.
3.
Sołtan W, Gołębiowska E, Limon J. Choroba Huntingtona – trzy punkty widzenia. Forum Med Rodz. 2011; 5: 108–114.
4.
Kępczyński Ł, Łopatyńska K. Choroba Huntingtona – obraz kliniczny u dzieci i młodzieży. Klin Pediatr. 2010; 18(1): 65–68.
5.
Zielonka D. Objawy, patogeneza i dostępne obecnie możliwości leczenia farmakologicznego choroby Huntingtona. Europejska Sieć Choroby Huntingtona. Neuropsychiatr Neuropsychol. 2009; 4: 10–16.
6.
Kloos AD, Kegelmyer DA, White SE, et al. The impact of different types of assistive devices on gait measures and safety in Huntington’s disease. PloS One 2012; 7(2): 1–7.
7.
Ehrnhoefer DE, Wong BKY, Hayden MR. Convergent pathogenic pathways in Alzheimer’s and Huntington disease: Shared target for drug development. Nat Rev Drug Discov. 2012; 10(11): 853–867.
8.
Feigin A, Zgaljardic D. Współczesne poglądy na chorobę Huntingtona: implikacje kliniczne dotyczące leczenia eksperymentalnego. Neurologia 2003; 2: 14–19.
9.
Veenhuizen RB, Kootstra B, Vink W, et al. Coordinated multidisciplinary care for ambulatory Huntington’s disease patients. Evaluation of 18 months of implementation. Orph J Rare Dis. 2011; 6: 1–6.
10.
Sari Y. Potential drugs and methods for preventing or delaying the progression of Huntington’s disease. Recent Pat CNS Drug Discover. 2011; 6(2): 80–90.
11.
Ross RAC. Huntington’s disease: a clinical review. Orph J Rare Dis. 2010; 5(40): 1–8.
12.
Heemskerk A, Ross R. Dysphagia In Huntington’s disease: a review. Dysphagia 2011; 26: 62–66.
13.
Szczudlik A, Rudzińska M, Zielonka D. Choroba Huntingtona – obecny stan wiedzy. Pol Przegl Neurol. 2008; 4, supl. A: 94–96.
14.
Tibben A. Impact of Huntington’s across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet. 2011; 80: 235–239.
15.
Carlozzi NE, Tulsky DS. Identification of Health-Related Quality of Life (HRQOL) issues relevant to individuals with HD. J Health Psychol. 2013; 18(2): 212–225.
16.
Koszewska I, Bzinkowska D. Depresja w chorobach neurologicznych – problem diagnostyczny i terapeutyczny. Przew Lek. 2005; 9, 20: 22–26.
17.
Krogias Ch, Strassburger K, Eyding J, et al. Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci. 2011; 36(3): 187–194.
18.
Dorsey ER. Characterization of large group of individuals with Huntington disease and their relatives enrolled in the cohort study. PloS One 2012; 16: 1–10.
19.
Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011; 11(5): 474–483.
20.
De Langavant LC, Fenelon G, Benisty S, et al. Awareness of memory deficit in early stage Huntington’s disease. PloS One 2013; 8(4): 1–10.
21.
Sitek E, Sołtan W, Sławek J. Rola neuropsychologa w diagnostyce i leczeniu choroby Huntingtona. Post Psychiatr Neurol. 2011; 20(1): 23–31.
22.
Sitek E, Sułtan W, Robowski P, et al. Poor insight into memory impairment in patients with Huntington disease. Neurol Neurochir Pol. 2012; 46(4): 318–325.
23.
hanjee A, Anand K, Bajaj BK. Hypersexual features in Huntington’s disease. Singapore Med J. 2011; 52(6): 131–133.
24.
Banaszkiewicz K, Sitek EJ, Rudzińska M, et al. Huntington’s disease from the patient, caregiver and physician’s perspectives: three sides of the same coin? J Neural Transm. 2012; 119: 1361–1365.
| eISSN: | 2084-4905 |
| ISSN: | 2083-4543 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
